Related Experiment Videos
Phase 1 clinical trials
1Dermatopharmacology Division, Department of Dermatology, Brown University School of Medicine, Providence, Rhode Island, USA.
Background:
In the United States, drug development and approval is a complex process regulated by the Food and Drug Administration under the authority outlined in the Code of Federal Regulation. The goal of this multi-step process is to determine safety and efficacy of new therapeutic entities. Initially, exposure of humans to new therapeutic agents is accomplished in a graded and limited fashion. This approach seeks to minimize risks to study participants from exposure to damaging agents. During early phases, limiting exposure to a few individuals results in the accumulation of preliminary data on pharmacology, short-term toxicity, and efficacy. The inherent limitations of this process necessitate careful critique and caution in extrapolation of phase 1 data.
Objectives:
The purpose of this article is to provide a review of the drug approval process focusing on phase 1 trials, which are the earliest human exposure to a new drug. The purpose, variations, and significance of phase 1 trials are described, and a framework is provided to critically evaluate data published from these trials.
Conclusions:
Phase 1 trials are primarily designed to accumulate short-term safety (toxicity) and pharmacological data. Although preliminary efficacy may be addressed ("proof of concept" efficacy), it is a secondary endpoint. The numbers of patients are small, the numbers of patients receiving efficacious doses are very small, and controls are absent. Evaluation of efficacy and of long-term toxicity requires longer, larger, and controlled studies.
Insights
Phase 1 clinical trials focus on early safety and pharmacology of new drugs in limited human exposure. While preliminary efficacy may be observed, robust evaluation requires larger, controlled studies.
Area of Science:
- Pharmacology
- Clinical Trials
- Drug Development
Background:
- The U.S. Food and Drug Administration (FDA) regulates drug approval through a multi-step process.
- Early human exposure to new drugs occurs in a graded manner to minimize participant risk.
- Phase 1 trials provide initial data on pharmacology, short-term toxicity, and potential efficacy.
Purpose of the Study:
- To review the drug approval process, emphasizing Phase 1 trials.
- To describe the purpose, variations, and significance of Phase 1 trials.
- To offer a framework for critically evaluating Phase 1 trial data.
Main Methods:
- Review of the drug approval process and Phase 1 trial design.
- Analysis of data collection and interpretation in early-stage drug development.
- Framework development for critical appraisal of Phase 1 trial outcomes.
Main Results:
- Phase 1 trials prioritize short-term safety (toxicity) and pharmacological data.
- Preliminary efficacy (proof of concept) is a secondary endpoint in Phase 1.
- Small patient numbers and lack of controls limit definitive efficacy conclusions.
Conclusions:
- Phase 1 trials are crucial for initial safety and pharmacology assessment.
- Efficacy and long-term toxicity require larger, controlled studies.
- Critical evaluation of Phase 1 data necessitates understanding its inherent limitations.